Online testing tool identifies people likely to benefit from genetic testing for inherited risk for certain cancers

byDana-Farber Cancer InstituteCredit: Unsplash/CC0 Public DomainAn online tool developed by researchers and physicians at Dana-Farber Cancer Institute can accurately and rapidly identify people

Updated on: December 18,2023 24

Online testing tool identifies people likely to benefit from genetic testing for inherited risk for certain cancers

byDana-Farber Cancer InstituteCredit: Unsplash/CC0 Public DomainAn online tool developed by researchers and physicians at Dana-Farber Cancer Institute can accurately and rapidly identify people

Updated on:December 18,2023 24

Scientists develop powerful AI algorithm to gain new insights into deadly glioblastoma

by Sylvester Comprehensive Cancer CenterThe SPHINKS network for the precision targeting of master kinases in glioblastoma. Credit: Antonio Iavarone, M.D.Scientists at Sylvester Comprehensive Cancer Ce

Updated on: December 27,2023 10

Scientists develop powerful AI algorithm to gain new insights into deadly glioblastoma

by Sylvester Comprehensive Cancer CenterThe SPHINKS network for the precision targeting of master kinases in glioblastoma. Credit: Antonio Iavarone, M.D.Scientists at Sylvester Comprehensive Cancer Ce

Updated on:December 27,2023 10

New clue discovered as to how and why cancer cells spread

by Gillian Rutherford,University of AlbertaViscosity enhances cell migration and promotes an ARP2/3-mediated dense actin network at the leading edge.a,b, Speeds of MDA-MB-231 cells (a) and

Updated on: December 22,2023 16

New clue discovered as to how and why cancer cells spread

by Gillian Rutherford,University of AlbertaViscosity enhances cell migration and promotes an ARP2/3-mediated dense actin network at the leading edge.a,b, Speeds of MDA-MB-231 cells (a) and

Updated on:December 22,2023 16

Camizestrant may be superior to fulvestrant in patients with hormone receptor-positive, HER2-negative breast cancer

byAmerican Association for Cancer ResearchCredit: Pixabay/CC0 Public DomainThe next-generation selective estrogen receptor degrader (SERD) camizestrant improved progression-free survival, compar

Updated on: December 21,2023 21

Camizestrant may be superior to fulvestrant in patients with hormone receptor-positive, HER2-negative breast cancer

byAmerican Association for Cancer ResearchCredit: Pixabay/CC0 Public DomainThe next-generation selective estrogen receptor degrader (SERD) camizestrant improved progression-free survival, compar

Updated on:December 21,2023 21

Single-cell 'atlas' reveals origin of an aggressive brain tumor

byCincinnati Children's Hospital Medical CenterChartshows that mice with reduced activity of either the SOX11 or HNRNOH1 genes had longer survival times when induced to develop medullo

Updated on: December 20,2023 10

Single-cell 'atlas' reveals origin of an aggressive brain tumor

byCincinnati Children's Hospital Medical CenterChartshows that mice with reduced activity of either the SOX11 or HNRNOH1 genes had longer survival times when induced to develop medullo

Updated on:December 20,2023 10

Entrectinib effective, well-tolerated against ROS1 and NTRK lung cancers, especially with brain metastases

by Garth Sundem,CU Anschutz Medical CampusRobert C. Doebele, MD, PhD. Credit: CU Anschutz Medical CampusPooled analysis of three phase 1 and 2 clinical trials published online ahead of print in

Updated on: December 22,2023 10

Entrectinib effective, well-tolerated against ROS1 and NTRK lung cancers, especially with brain metastases

by Garth Sundem,CU Anschutz Medical CampusRobert C. Doebele, MD, PhD. Credit: CU Anschutz Medical CampusPooled analysis of three phase 1 and 2 clinical trials published online ahead of print in

Updated on:December 22,2023 10

Pathogenesis to management of hepatocellular carcinoma

by Impact JournalsMolecular pathways and targeted therapeutics in hepatocellular carcinoma. Abbreviations: APC: antigen presenting cell; AXL is a cell surface receptor tyrosine kinase, part of the TAM

Updated on: December 22,2023 12

Pathogenesis to management of hepatocellular carcinoma

by Impact JournalsMolecular pathways and targeted therapeutics in hepatocellular carcinoma. Abbreviations: APC: antigen presenting cell; AXL is a cell surface receptor tyrosine kinase, part of the TAM

Updated on:December 22,2023 12

Immunotherapy improves survival in metastatic or recurrent head and neck cancer

byEuropean Society for Medical OncologyProf Barbara Burtness, Yale School of Medicine and Co-Director, Development Therapeutics Research Program, Yale Cancer Center, New Haven, US, study author.

Updated on: December 18,2023 18

Immunotherapy improves survival in metastatic or recurrent head and neck cancer

byEuropean Society for Medical OncologyProf Barbara Burtness, Yale School of Medicine and Co-Director, Development Therapeutics Research Program, Yale Cancer Center, New Haven, US, study author.

Updated on:December 18,2023 18

Vitamin B6, leukemia's deadly addiction

by Brian Stallard,Cold Spring Harbor LaboratoryThe PDXK enzyme manages the activity of B6, activating it when it is time for cells to divide. In AML, cancerous cells (green) can take advantage o

Updated on: December 22,2023 22

Vitamin B6, leukemia's deadly addiction

by Brian Stallard,Cold Spring Harbor LaboratoryThe PDXK enzyme manages the activity of B6, activating it when it is time for cells to divide. In AML, cancerous cells (green) can take advantage o

Updated on:December 22,2023 22

Incidence of early-onset gastric cancer increasing in the U.S.

(HealthDay)—The incidence of early-onset gastric cancer has been increasing in the United States, and it seems to be distinct clinically and genetically from late-onset gastric cancer, according to a

Updated on: December 22,2023 15

Incidence of early-onset gastric cancer increasing in the U.S.

(HealthDay)—The incidence of early-onset gastric cancer has been increasing in the United States, and it seems to be distinct clinically and genetically from late-onset gastric cancer, according to a

Updated on:December 22,2023 15

Developing therapies for treatment-resistant prostate cancer: Small clinical trial shows 40% progression-free survival

byCedars-Sinai Medical CenterGraphical abstract. Credit:Molecular Therapy(2022). DOI: 10.1016/j.ymthe.2022.08.019Investigators from Cedars-Sinai Cancer have identified an investigati

Updated on: December 26,2023 6

Developing therapies for treatment-resistant prostate cancer: Small clinical trial shows 40% progression-free survival

byCedars-Sinai Medical CenterGraphical abstract. Credit:Molecular Therapy(2022). DOI: 10.1016/j.ymthe.2022.08.019Investigators from Cedars-Sinai Cancer have identified an investigati

Updated on:December 26,2023 6

Study of rare cancer identifies patients at highest risk of metastasis and those who would respond to immunotherapy

byThe Spanish National Cancer Research CentreCNIO researchers Bruna Calsina (left) and Mercedes Robledo. Credit: Laura M. Lombardía, CNIOPheochromocytoma is a rare tumor, with an incidence of th

Updated on: December 23,2023 13

Study of rare cancer identifies patients at highest risk of metastasis and those who would respond to immunotherapy

byThe Spanish National Cancer Research CentreCNIO researchers Bruna Calsina (left) and Mercedes Robledo. Credit: Laura M. Lombardía, CNIOPheochromocytoma is a rare tumor, with an incidence of th

Updated on:December 23,2023 13